ArticleScientific reports2026
Network pharmacology-guided optimization of Semen Sojae Praeparatum fermentation for enhanced anti-influenza efficacy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Semen Sojae Praeparatum (SSP), a traditional Chinese medicine derived from fermented black soybeans, has been historically used to treat febrile epidemics ("Wen Bing") with symptoms akin to influenza. This study integrated network pharmacology, molecular docking, in vitro pharmacodynamics and HPLC-based fingerprint and quality evaluation to elucidate SSP's anti-influenza mechanisms and optimize its fermentation process. Network pharmacology identified genistein and daidzein as key bioactive constituents targeting hub proteins TNF, AKT1, EGFR, SRC, and MMP9, which mediate pathological process in influenza. Molecular docking confirmed their strong binding affinities, particularly to lung-expressed AKT1 and SRC both of which are upstream activating kinases of the NF-κB p65 signaling pathway. Guided by these computational predictions, genistein and daidzein were evaluated in A549 cells using LPS and H
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.